topics amgen-v-sandoz 
The IPKat
DECEMBER 22, 2023
G2/21 and the mysteries of plausibility The topic that this Kat has spent the most electronic ink on this year is undoubtedly G 2/21. After a flurry of decisions at the start of the year , the Boards of Appeal have gone rather silent on the topic of ViCo oral proceedings. This is one to watch for 2024.
Fish & Richardson Trademark & Copyright Thoughts
JANUARY 11, 2022
For example, Amgen recently announced that it has Phase 3 studies under way to support interchangeability status for its adalimumab and ustekinumab biosimilars, Amjevita ™ and ABP 654, respectively. Neulasta ® (Amgen). Avsola ® (Amgen). Ziextenzo ® (Sandoz). Kanjinti ® (Amgen/ Allergan). Enbrel ® (Amgen).
Expert insights. Personalized for you.
110 
Let's personalize your content